Internal Reference Number: FOI_8629
Date Request Received: 06/05/2025 00:00:00
Date Request Replied To: 04/08/2025 00:00:00
This response was sent via: By Email
Request Summary: Biologics Rheumatology
Request Category: Companies
| Question Number 1: Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Baricitinib [Olumiant] • Bimekizumab [Bimzelx] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Filgotinib [Jyseleca] • Golimumab [Simponi] • Guselkumab [Tremfya] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Rituximab [MabThera] • Rituximab Biosimilars • Sarilumab [Kevzara] • Secukinumab [Cosentyx] • Tocilizumab [Ro Actemra] • Tocilizumab Biosimilars • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara] • Ustekinumab Biosimilar | |
| Answer To Question 1: • Abatacept [Orencia] - 44 • Adalimumab [Humira] - 28 • Adalimumab Biosimilars - 402 • Apremilast [Otezla] - 5 • Baricitinib [Olumiant] - 25 • Bimekizumab [Bimzelx] - 11 • Certolizumab [Cimzia] - 35 • Etanercept [Enbrel] - 9 • Etanercept Biosimilars - 134 • Filgotinib [Jyseleca] - 24 • Golimumab [Simponi] - 9 • Guselkumab [Tremfya] - 18 • Infliximab [Remicade] - 5 • Infliximab Biosimilars – 2 + 5 • Ixekizumab [Taltz] - <5 • Risankizumab [Skyrizi] - 0 • Rituximab [MabThera] - 0 • Rituximab Biosimilars - 0 • Sarilumab [Kevzara] - <5 • Secukinumab [Cosentyx] - 11 • Tocilizumab [Ro Actemra] - 33 • Tocilizumab Biosimilars - 0 • Tofacitinib [Xeljanz] - 18 • Upadacitinib [Rinvoq] - 63 • Ustekinumab [Stelara] - 0 • Ustekinumab Biosimilar - <5 | |
| Question Number 2: Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs. • Adalimumab [Humira] • Adalimumab Biosimilars • Bimekizumab [Bimzelx] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Golimumab [Simponi] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Secukinumab [Cosentyx] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] | |
| Answer To Question 2: • Adalimumab [Humira] 0 • Adalimumab Biosimilars 22 • Bimekizumab [Bimzelx] 0 • Certolizumab [Cimzia] <5 • Etanercept [Enbrel] <5 • Etanercept Biosimilars <5 • Golimumab [Simponi] <5 • Infliximab [Remicade] 0 • Infliximab Biosimilars 13 • Ixekizumab [Taltz] <5 • Secukinumab [Cosentyx] 0 • Tofacitinib [Xeljanz] 0 • Upadacitinib [Rinvoq] <5 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
